Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
AS-1411 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
AS-1411: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CUE-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
CUE-101: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Oprozomib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
Oprozomib: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
IGFBP1 Biologics Sequence Review Report 2026: Insulin-like growth factor-binding protein 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IGFBP1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IFITM5 Biologics Sequence Review Report 2026: Interferon-induced transmembrane protein 5 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFITM5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IFITM1 Biologics Sequence Review Report 2026: Interferon-induced transmembrane protein 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFITM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IGFALS Biologics Sequence Review Report 2026: Insulin-like growth factor-binding protein complex acid labile subunit Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IGFALS protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IBSP Biologics Sequence Review Report 2026: Integrin-binding sialoprotein Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IBSP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
DSCAM Biologics Sequence Review Report 2026: Cell adhesion molecule DSCAM Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of DSCAM protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
HDGF Biologics Sequence Review Report 2026: Hepatoma-derived growth factor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of HDGF protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
BCAM Biologics Sequence Review Report 2026: Basal cell adhesion molecule Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of BCAM protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CHL1 Biologics Sequence Review Report 2026: Neural cell adhesion molecule L1-like protein Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of CHL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.